Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro

Journal of Medicinal Chemistry

Volumn 51, Issue 13, 2008, Pages 3895-3904

  Gediya, Lalji K ^a   Khandelwal, Aakanksha ^a   Patel, Jyoti ^a,b   Belosay, Aashvini ^a,c   Sabnis, Gauri ^a   Mehta, Jhalak ^a   Purushottamachar, Puranik ^a   Njar, Vincent C O ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (BUTANOYLOXYMETHYL)PHENYL 3,7 DIMETHYL 9 (2,6,6 TRIMETHYLCYCLOHEX 1 ENYL)NONA 2,4,6,8 TETRAENOATE; 4 [[N [2 [(4 (ACETYLAMINO)PHENYL]CARBONYLAMINO]PHENYLCARBAMOYLOXY]METHYL]PHENYL 3,7 DIMETHYL 9 (2,6,6 TRIMETHYLCYCLOHEX 1 ENYL)NONA 2,4,6,8 TETRAENOATE; 4 [[N [2 [[4 [[[(3 PYRIDYLMETHYL)OXYCARBONYL]METHYL]AMINO]PHENYL]CARBONYLAMINO]PHENYL]CARBAMOYLOXY] METHYL]PHENYL 3,7 DIMETHYL 9 (2,6,6 TRIMETHYLCYCLOHEX 1 ENYL)NONA 2,4,6,8 TETRAENOATE; [[N [N [2 [4 [(3 PYRIDYLMETHOXY)CARBONYLAMINO]METHYL]PHENYL]CARBONYLAMINO]PHENYL]CARBAMOYLCARBAMO YLOXY]METHYL 3,7 DIMETHYL 9 (2,6,6 TRIMETHYLCYCLOHEX 1 ENYL)NONA 2,4,6,8 TETRAENOATE; [N [[N [2 [(4 (ACETYLAMINO)PHENYL]CARBONYLAMINOPHENYL]CARBAMOYL]METHYL]CARBAMOYLOXY]METHYL 3,7 DIMETHYL 9 (2,6,6 TRIMETHYLCYCLOHEX 1 ENYL)NONA 2,4,6,8 TETRAENOATE; BUTYRIC ACID; CARBONIC ACID DERIVATIVE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PRODRUG; RETINOIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CULTURE MEDIUM; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARBAMATES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; MALE; MICE; MICE, SCID; MOLECULAR STRUCTURE; PRODRUGS; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TRETINOIN;

EID: 46849096306     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8001839     Document Type: Article

References (48)

1. Altucci, L.; Gronemeyer, H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 2001, 1, 181-193.
2. Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans, R. M. The nuclear receptor superfamily: the second decade. Cell 1995, 83, 835-839.
3. Altucci, L.; Leibowitz, M. D.; Ogilvie, K. M.; de Lera, A. R.; Gronemeyer, H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discovery 2007, 6, 793-810.
4. Reynolds, C. P.; Matthay, K. K.; Villablanca, J. G.; Maurer, B. J. Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 2003, 197, 185-192.
5. Freemantle, S. J.; Spinella, M. J.; Dmitrovsky, E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003, 22, 7305-7315.
6. Sun, S. Y.; Wan, H.; Yue, P.; Hong, W. K.; Lotan, R. Evidence that retinoic acid receptor beta induction by retinoids is important for tumor cell growth inhibition. J. Biol. Chem. 2000, 275, 17149-17153.
7. Sirchia, S. M.; Ferguson, A. T.; Sironi, E.; Subramanyan, S.; Orlandi, R.; Sukumar, S.; Sacchi, N. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 2000, 19, 1556-1563.
8. Widschwendter, M.; Berger, J.; Hermann, M.; Muller, H. M.; Amberger, A.; Zeschnigk, M.; Widschwendter, A.; Abendstein, B.; Zeimet, A. G.; Daxenbichler, G.; Marth, C. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J. Natl. Cancer Inst. 2000, 92, 826-832.
9. Johnstone, R. W.; Licht, J. D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003, 4, 13-18.
10. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discovery 2006, 5, 769-784.
11. Baylin, S. B.; Esteller, M.; Rountree, M. R.; Bachman, K. E.; Schuebel, K.; Herman, J. G. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 2001, 10, 687-692.
12. Herman, J. G.; Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349, 2042-2054.
13. Lin, R. J.; Nagy, L.; Inoue, S.; Shao, W.; Miller, W. H., Jr.; Evans, R. M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 391, 811-814.
14. Ogryzko, V. V.; Schiltz, R. L.; Russanova, V.; Howard, B. H.; Nakatani, Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996, 87, 953-959.
15. Wolffe, A. P. Transcriptional control. Sinful repression. Nature 1997, 387, 16-17.
16. Grignani, F.; De Matteis, S.; Nervi, C.; Tomassoni, L.; Gelmetti, V.; Cioce, M.; Fanelli, M.; Ruthardt, M.; Ferrara, F. F.; Zamir, I.; Seiser, C.; Grignani, F.; Lazar, M. A.; Minucci, S.; Pelicci, P. G. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998, 391, 815-818.
17. He, L. Z.; Guidez, F.; Tribioli, C.; Peruzzi, D.; Ruthardt, M.; Zelent, A.; Pandolfi, P. P. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat. Genet. 1998, 18, 126-135.
18. Warrell, R. P., Jr.; He, L. Z.; Richon, V.; Calleja, E.; Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 1998, 90, 1621-1625.
19. Pili, R.; Kruszewski, M. P.; Hager, B. W.; Lantz, J.; Carducci, M. A. Combination of phenylbutyrate and 13-cis-retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. 2001, 61, 1477-1485.
20. Sirchia, S. M.; Ren, M.; Pili, R.; Sironi, E.; Somenzi, G.; Ghidoni, R.; Toma, S.; Nicolo, G.; Sacchi, N. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 2002, 62, 2455-2461.
21. Gediya, L. K.; Belosay, A.; Khandelwal, A.; Purushottamachar, P.; Njar, V. C. Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg. Med. Chem. 2008, 16, 3352-3360.
22. Gediya, L. K.; Chopra, P.; Purushottamachar, P.; Maheshwari, N.; Njar, V. C. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J. Med. Chem. 2005, 48, 5047-5051.
23. Hess-Stumpp, H.; Bracker, T. U.; Henderson, D.; Politz, O. MS-275, a potent orally available inhibitor of histone deacetylases - the development of an anticancer agent. Int. J. Biochem. Cell Biol. 2007, 39, 1388-1405.
24. Wang, X. F.; Qian, D. Z.; Ren, M.; Kato, Y.; Wei, Y.; Zhang, L.; Fansler, Z.; Clark, D.; Nakanishi, O.; Pili, R. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin. Cancer Res. 2005, 11, 3535-3542.
25. Verheul, H. M.; Qian, D. Z.; Carducci, M. A.; Pili, R. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemother. Pharmacol. 2007, 60, 329-339.
26. Glaser, K. B. HDAC inhibitors: Clinical update and mechanism-based potential. Biochem. Pharmacol. 2007, 74, 659-671.
27. Richon, V. M.; Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; Ngo, L.; Civoli, F.; Breslow, R.; Rifkind, R. A.; Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5705-5708.
28. Kelly, W. K.; Richon, V. M.; O'Connor, O.; Curley, T.; MacGregor-Curtelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, M.; Cordon-Cordo, C.; Chiao, J. H.; Rifkind, R.; Marks, P. A.; Scher, H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 2003, 9, 3578-3588.
29. Nudelman, A.; Rephaeli, A. Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity. J. Med. Chem. 2000, 43, 2962-2966.
30. Mann, K. K.; Rephaeli, A.; Colosimo, A. L.; Diaz, Z.; Nudelman, A.; Levovich, I.; Jing, Y.; Waxman, S.; Miller, W. H., Jr. A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis. Mol. Cancer Res. 2003, 1, 903-912.
31. Gediya, L. K., K.; Mehta, J.; Purashottamachar, P.; Njar, V. C. O. Mutual prodrugs of all-trans-retinoic acid and histone deacetylase inhibitors: potent anticancer agents. 232nd American Chemical Society (ACS) National Meeting, Chicago, IL, March 25-29, 2007 American Chemical Society: Washington, DC, 2007; abstract no. MEDI 286.
32. Nudelman, A.; Ruse, M.; Aviram, A.; Rabizadeh, E.; Shaklai, M.; Zimrah, Y.; Rephaeli, A. Novel anticancer prodrugs of butyric acid. 2. J. Med. Chem. 1992, 35, 687-694.
33. Rephaeli, A.; Rabizadeh, E.; Aviram, A.; Shaklai, M.; Ruse, M.; Nudelman, A. Derivatives of butyric acid as potential antineoplastic agents. Int. J. Cancer 1991, 49, 66-72.
34. Alexander, J.; Cargill, R.; Michelson, S. R.; Schwam, H. (Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes. J. Med. Chem. 1988, 31, 318-322.
35. Alexander, J.; Fromtling, R. A.; Bland, J. A.; Pelak, B. A.; Gilfillan, E. C. (Acyloxy)alkyl carbamate prodrugs of norfloxacin. J. Med. Chem. 1991, 34, 78-81.
36. Pochopin, N. L.; Charman, W. N.; Stella, V. J. Pharmacokinetics of dapsone and amino acid prodrugs of dapsone. Drug Metab. Dispos. 1994, 22, 770-775.
37. Greenwald, R. B.; Pendri, A.; Conover, C. D.; Zhao, H.; Choe, Y. H.; Martinez, A.; Shum, K.; Guan, S. Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds. J. Med. Chem. 1999, 42, 3657-3667.
38. Florent, J. C.; Dong, X.; Gaudel, G.; Mitaku, S.; Monneret, C.; Gesson, J. P.; Jacquesy, J. C.; Mondon, M.; Renoux, B.; Andrianomenjanahary, S.; Michel, S.; Koch, M.; Tillequin, F.; Gerken, M.; Czech, J.; Straub, R.; Bosslet, K. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J. Med. Chem. 1998, 41, 3572-3581.
39. Hulsman, N.; Medema, J. P.; Bos, C.; Jongejan, A.; Leurs, R.; Smit, M. J.; de Esch, I. J.; Richel, D.; Wijtmans, M. Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J. Med. Chem. 2007, 50, 2424-2431.
40. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discovery Today 2004, 9, 641-651.
41. de Groot, F. M.; de Bart, A. C.; Verheijen, J. H.; Scheeren, H. W. Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin. J. Med. Chem. 1999, 42, 5277-5283.
42. Gediya, L.; Belosay, A.; Khandelwal, A.; Purushottamachar, P.; Njar, V. C. O. Improved synthesis of histone deacetylase inhibitors (HDACIs) (MS-275 and CI-994) and inhibitory effects of HDACIs alone and in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg. Med. Chem. 2008, 16, 3352-3360.
43. Nudelman, A.; Levovich, I.; Cutts, S. M.; Phillips, D. R.; Rephaeli, A. The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters. J. Med. Chem. 2005, 48, 1042-1054.
44. Patel, J. B.; Huynh, C. K.; Handratta, V. D.; Gediya, L. K.; Brodie, A. M.; Goloubeva, O. G.; Clement, O. O.; Nanne, I. P.; Soprano, D. R.; Njar, V. C. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice. J. Med. Chem. 2004, 47, 6716-6729.
45. Patel, J. B.; Mehta, J.; Belosay, A.; Sabnis, G.; Khandelwal, A.; Brodie, A. M.; Soprano, D. R.; Njar, V. C. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br. J. Cancer 2007, 96, 1204-1215.
46. Belosay, A., Jelovac, D., Long, B., Njar, V. C. O., Brodie, A. Histone deacetylase inhibitors synergize with retinoic acid metabolism blocking agent (VN/14-1) in letrozole resistant human breast cancer cells. The Endocrine Society's 88th Annual Meeting, Boston, MA, June 24-27, 2006; Endocrine Society: Chevy Chase, MD, 2006.
47. Sabnis, G. J.; Jelovac, D.; Long, B.; Brodie, A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res. 2005, 65, 3903-3910.
48. Wu, X.; Chen, H.; Parker, B.; Rubin, E.; Zhu, T.; Lee, J. S.; Argani, P.; Sukumar, S. HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res. 2006, 66, 9527-9534.